The FDA cleared Baxter Internationals' synthetic bone graft substitute Actifuse Flow for use in several orthopedic surgical procedures, Verdict Medical Devices reports.
Here are five facts:
1. Actifuse Flow is a prepackaged delivery syringe designed for use in pelvis, extremities and posterolateral spine orthopedic surgeries.
2. The graft substitute temporarily fills in the bone and is eventually replaced by the patient's own bone during the healing process.
3. The syringe design facilitates precise positioning for filling small bone defects and complex gaps. The graft will be available in 1.5 ml, 3 ml and 5 ml sizes.
4. Baxter plans to launch Actifuse Flow commercially within the coming months.
5. Actifuse Flow is part of Baxter's osteobiologics surgery portfolio, along with Actifuse ABX, Actifuse Shape, Actifuse MIS and Altapore. The products use silicate-substituted technology to increase silicon levels for bone formation.